GeneBioTech Co Ltd
KOSDAQ:086060
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 045
5 550
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
GeneBioTech Co Ltd
Cash from Operating Activities
GeneBioTech Co Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GeneBioTech Co Ltd
KOSDAQ:086060
|
Cash from Operating Activities
â‚©3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Operating Activities
â‚©812.1B
|
CAGR 3-Years
42%
|
CAGR 5-Years
22%
|
CAGR 10-Years
34%
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cash from Operating Activities
â‚©162.4B
|
CAGR 3-Years
33%
|
CAGR 5-Years
43%
|
CAGR 10-Years
26%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Operating Activities
â‚©82.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
30%
|
CAGR 10-Years
52%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash from Operating Activities
-â‚©33.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
D
|
DND PharmaTech Inc
KOSDAQ:347850
|
Cash from Operating Activities
-â‚©21.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
GeneBioTech Co Ltd
Glance View
Gene Bio Tech Co., Ltd. engages in the manufacture of fermented biomass. The company is headquartered in Gongju, Chungcheongnam-Do. The company went IPO on 2006-04-28. is a company mainly engaged in the production and sale of feed additives and animal drugs. Along with subsidiaries, the Company operates its business through two segments. The Additive segment is involved in the manufacturing and sale of fermented products and bio starches. The Animal Drug segment is involved in the manufacturing and sale of livestock and fish medicine. The main products include vitamins, minerals, antibiotics, nutrients, immune stimulators, digestion and absorption promoters, among others. The firm distributes its products within the domestic market and to overseas markets, including America.
See Also
What is GeneBioTech Co Ltd's Cash from Operating Activities?
Cash from Operating Activities
3B
KRW
Based on the financial report for Jun 30, 2025, GeneBioTech Co Ltd's Cash from Operating Activities amounts to 3B KRW.
What is GeneBioTech Co Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-3%
Over the last year, the Cash from Operating Activities growth was 44%.